Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
Public ClinicalTrials.gov record NCT03930615. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT)
Study identification
- NCT ID
- NCT03930615
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 220 participants
Conditions and interventions
Conditions
Interventions
- Letermovir Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 20, 2019
- Primary completion
- Oct 26, 2021
- Completion
- Mar 15, 2022
- Last update posted
- Aug 21, 2024
2019 – 2022
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center ( Site 0158) | Duarte | California | 91010 | — |
| University of California Davis Medical Center ( Site 0156) | Sacramento | California | 95817 | — |
| University of Miami, Sylvester Comprehensive Cancer Center ( Site 0160) | Miami | Florida | 33136 | — |
| Indiana Blood and Marrow Transplantation ( Site 0175) | Indianapolis | Indiana | 46237 | — |
| Brigham & Women's Hospital ( Site 0161) | Boston | Massachusetts | 02115 | — |
| John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0174) | Hackensack | New Jersey | 07601 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0164) | New York | New York | 10065 | — |
| Duke University Medical Center ( Site 0169) | Durham | North Carolina | 27710 | — |
| The University of Texas MD Anderson Cancer Center ( Site 0154) | Houston | Texas | 77030 | — |
| Fred Hutchinson Cancer Research Center ( Site 0152) | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03930615, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2024 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03930615 live on ClinicalTrials.gov.